BioNxt Solutions Advances MS Drug with Key Preclinical Data

BioNxt Solutions has achieved a significant milestone in the development of its multiple sclerosis (MS) treatment. Recent preclinical data indicates the company's proprietary oral dissolving film (ODF) delivers the active ingredient more efficiently than conventional tablets. Despite this scientific progress, the market response has been muted, with investors taking a measured view of the developments.

The company’s approach centers on optimizing established drugs through advanced delivery systems. By utilizing Cladribin, an already approved and effective pharmaceutical agent, BioNxt sidesteps many of the risks inherent in developing entirely new chemical compounds. This latest success validates that strategy.

The progress is further supported by an expanding intellectual property portfolio. In November 2025, the firm secured a Eurasian patent, protecting its technology until 2043 across a market encompassing over 200 million people. Operational advances, however, have not yet translated into share price momentum. The equity closed at €0.30 on Tuesday, marking a decline of approximately 24% for the month. It remains significantly distant from its 52-week high, with a gap exceeding 54%.

Should investors sell immediately? Or is it worth buying Bionxt Solutions?

Superior Efficacy in Animal Studies

The core of the recent announcement lies in results from a preclinical study on large animals. BioNxt directly compared its Cladribin-based ODF with the established standard tablet used for MS. The investigation yielded a clear outcome: the film demonstrated superior bioavailability compared to the pill form.

This technical achievement has direct implications for potential therapeutic use. Enhanced absorption of the active substance could enable lower dosages, which may reduce dose-dependent side effects. Furthermore, the dissolving film presents a crucial alternative for patients with dysphagia (swallowing difficulties), who represent a considerable portion of the MS patient population.

Pivotal Human Study on the Horizon

Attention now turns fully to the upcoming comparative bioequivalence study in humans, scheduled to commence in early 2026. The data recently obtained from the animal model is essential for precisely calibrating the dosage for this next clinical phase. A successful completion of the human trial would represent the final major hurdle before BioNxt can seek regulatory approval for commercialization.